insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

MYMD · Mymd Pharmaceuticals, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue----------
Cost of Revenue----------
Gross Profit----------
R&D$510.5K-$356.4K$873.5K$1.55M-$707.7K$401.1K$1.20M-
SG&A$1.07M-$967.8K$894.3K$841.7K-$1.10M$1.02M$1.07M-
Total Operating Expenses----------
D&A----------
Operating Income($1.86M)-($1.79M)($1.87M)($2.47M)-($1.83M)($3.37M)($2.78M)-
Interest Expense----------
Income Tax----------
Net Income($1.24M)-($2.81M)($1.80M)($1.12M)-($1.93M)($9.57M)($9.80M)-
EPS - Basic($0.19)-($2.50)($0.18)($0.36)-($1.11)($4.54)($5.14)-
EPS - Diluted($0.19)-($2.50)($0.18)($0.36)-($1.11)($4.54)($5.14)-

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$1.13M$987.0K$6.90M$173.2K$73.2K$173.2K$1.19M$536.0K$225.7K$2.68M
Accounts Receivable----------
Inventory----------
Accounts Payable$1.38M$2.45M$3.18M$2.68M$2.59M$2.90M$4.16M$4.62M$3.86M$3.72M
Current Assets$13.71M$16.58M$11.15M$5.15M$6.78M$9.41M$12.03M$14.36M$2.46M$5.82M
Total Assets$38.29M$41.17M$37.23M$17.15M$18.78M$21.42M$24.04M$26.38M$14.49M$17.86M
Current Liabilities$3.69M$5.53M$6.53M$5.55M$4.94M$6.70M$6.99M$5.78M$3.97M$4.99M
Long-term Debt----------
Total Liabilities$14.60M$16.44M$15.91M$5.55M$4.94M$6.70M$6.99M$26.00M$4.25M$5.09M
Stockholders' Equity$20.72M$21.75M$14.32M$5.28M$8.69M$9.79M$16.78M$97.8K$9.94M$12.37M
Retained Earnings($145.65M)($144.12M)($137.56M)($133.85M)($131.08M)($129.14M)($126.00M)($123.32M)($112.98M)($101.98M)

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow($3.29M)---($2.64M)---($1.91M)-
Investing Cash Flow$2.97M---$2.54M---$732.0K-
Financing Cash Flow$453.9K-------($1.28M)-
CapEx$1.75M---------
Free Cash Flow($5.04M)---------

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income4.05---------
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets-3.2%--7.6%-10.5%-6.0%--8.0%-36.3%-67.6%-
Return on equity-6.0%--19.6%-34.0%-12.9%--11.5%-9780.3%-98.6%-
Return on invested capital----------
Liquidity
Current ratio3.713.001.710.931.371.401.722.480.621.17
Quick ratio3.713.001.710.931.371.401.722.480.621.17
Cash ratio0.310.181.060.030.010.030.170.090.060.54
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage----------
Equity multiplier1.851.892.603.252.162.191.43269.741.461.44
Liabilities / Assets0.380.400.430.320.260.310.290.990.290.28
Efficiency
Asset turnover----------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B----------
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)24.9%-2.0%44.4%11.2%-52.5%41.7%-7.5%-
Net income growth (YoY)-10.5%--45.7%81.2%88.5%---129.5%-548.3%-
EPS growth (YoY)47.2%--125.2%96.0%93.0%--1133.3%-4944.4%--
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)138.4%122.2%-14.6%5295.7%-12.5%-20.9%8.2%-99.1%-24.1%-15.8%

Peer comparison

Same SIC group: In Vitro & In Vivo Diagnostic Substances

CompanyRevenue (last FY)Net marginROE
VNRX$1.73M-1352.2%68.2%
QDEL$2.73B-41.5%-58.9%
MYGN$824.50M-44.4%-99.4%
LNTH$1.54B15.2%21.4%
IDXX$4.30B24.6%66.0%

Comparing MyMD Pharmaceuticals against the 5 most active filers in the same SIC group.